ALC-0159 | CAS#1849616-42-7 | PEG/lipid conjugate

MedKoo Cat#: 556014 | Name: ALC-0159

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ALC-0159 is a PEG/lipid conjugate (i.e. PEGylated lipid), specifically, it is the N,N-dimyristylamide of 2-hydroxyacetic acid, O-pegylated to a PEG chain mass of about 2 kilodaltons (corresponding to about 45-46 ethylene oxide units per molecule of N,N-dimyristyl hydroxyacetamide). It is a non-ionic surfactant by its nature. It has been deployed in the Pfizer-BioNTech SARS-CoV-2 mRNA vaccine that contains the active ingredient tozinameran.

Chemical Structure

ALC-0159

CAS#1849616-42-7

Theoretical Analysis

MedKoo Cat#: 556014

Name: ALC-0159

CAS#: 1849616-42-7

Chemical Formula: (C2H4O)nC31H63NO2

Exact Mass: 0.0000

Molecular Weight: 2450.00

Elemental Analysis:

Price and Availability

Size	Price	Availability
10mg	USD 150.00	Ready to ship
25mg	USD 250.00	Ready to ship
100mg	USD 450.00	Ready to ship
200mg	USD 750.00	Ready to ship
500mg	USD 1,650.00	Ready to ship
1g	USD 2,950.00	Ready to ship
2g	USD 5,250.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

ALC-0159; ALC 0159; ALC0159;

IUPAC/Chemical Name

2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide

InChi Key

BPWFJNQUTKVHIR-UHFFFAOYSA-N

InChi Code

InChI=1S/C33H67NO3/c1-4-6-8-10-12-14-16-18-20-22-24-26-28-34(33(35)32-37-31-30-36-3)29-27-25-23-21-19-17-15-13-11-9-7-5-2/h4-32H2,1-3H3

SMILES Code

CCCCCCCCCCCCCCN(CCCCCCCCCCCCCC)C(COCCOC)=O

Appearance

solid

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#A21T12K30

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

ALC-0159 is a polyethylene glycol (PEG) lipid conjugate that could be used as vaccine excipient.

In vitro activity:

ALC-0315 is an ionisable aminolipid that is responsible for mRNA compaction and aids mRNA cellular delivery and its cytoplasmic release through suspected endosomal destabilization. The LNPs in the Pfizer-BioNTech COVID-19 vaccine contain low levels (<2 mol %) of ALC-0159, which contributes to nanoparticle stabilization by a steric mechanism through its poly(ethylene glycol) (PEG) moiety. Considering their low ALC-0159 content, LNPs in the Pfizer-BioNTech COVID-19 vaccine most likely display a weak steric barrier of PEG. Reference: Mol Ther. 2021 Mar 3;29(3):898-900. https://pubmed.ncbi.nlm.nih.gov/33571463/

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMF	10.0	0.00
	Ethanol	1.0	0.00
	DMSO	100.0	0.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 2,450.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Moghimi SM. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines. Mol Ther. 2021 Mar 3;29(3):898-900. doi: 10.1016/j.ymthe.2021.01.030. Epub 2021 Feb 5. PMID: 33571463; PMCID: PMC7862013.

In vitro protocol:

In vivo protocol:

TBD

1: Carreño JM, Singh G, Tcheou J, Srivastava K, Gleason C, Muramatsu H, Desai P, Aberg JA, Miller RL, Study Group P, Pardi N, Simon V, Krammer F. mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations. Vaccine. 2022 Oct 6;40(42):6114-6124. doi: 10.1016/j.vaccine.2022.08.024. Epub 2022 Sep 15. PMID: 36115801; PMCID: PMC9474432. 2: Radice A, Fassio F, Meucci E, Iorno MCL, Macchia D. Potential culprits for immediate hypersensitivity reactions to BNT162b2 mRNA COVID-19 vaccine: not just PEG. Eur Ann Allergy Clin Immunol. 2021 Sep;53(5):240-242. doi: 10.23822/EurAnnACI.1764-1489.214. Epub 2021 Apr 29. PMID: 33913314.

1. Xue Y, Zhang Y, Zhong Y, Du S, Hou X, Li W, Li H, Wang S, Wang C, Yan J, Kang DD, Deng B, McComb DW, Irvine DJ, Weiss R, Dong Y. LNP-RNA-engineered adipose stem cells for accelerated diabetic wound healing. Nat Commun. 2024 Jan 25;15(1):739. doi: 10.1038/s41467-024-45094-5. PMID: 38272900; PMCID: PMC10811230. 2. Zhang W, Pfeifle A, Lansdell C, Frahm G, Cecillon J, Tamming L, Gravel C, Gao J, Thulasi Raman SN, Wang L, Sauve S, Rosu-Myles M, Li X, Johnston MJW. The Expression Kinetics and Immunogenicity of Lipid Nanoparticles Delivering Plasmid DNA and mRNA in Mice. Vaccines (Basel). 2023 Oct 11;11(10):1580. doi: 10.3390/vaccines11101580. PMID: 37896985; PMCID: PMC10610642. 3. Im SH, Chung Y, Duskunovic N, Choi H, Park SH, Chung HJ. Oligonucleotide-Linked Lipid Nanoparticles as a Versatile mRNA Nanovaccine Platform. Adv Healthc Mater. 2024 Oct 3:e2401868. doi: 10.1002/adhm.202401868. Epub ahead of print. PMID: 39363681. 4. Fazel F, Matsuyama-Kato A, Alizadeh M, Zheng J, Fletcher C, Gupta B, St-Denis M, Boodhoo N, Sharif S. A Marek's Disease Virus Messenger RNA-Based Vaccine Modulates Local and Systemic Immune Responses in Chickens. Viruses. 2024 Jul 18;16(7):1156. doi: 10.3390/v16071156. PMID: 39066318; PMCID: PMC11281610. 5. Xue Y, Hou X, Zhong Y, Zhang Y, Du S, Kang DD, Wang L, Wang C, Li H, Wang S, Liu Z, Tian M, Guo K, Cao D, Deng B, McComb DW, Purisic E, Dai J, Hamon P, Brown BD, Tsankova NM, Merad M, Irvine DJ, Weiss R, Dong Y. LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment. Nat Commun. 2025 Mar 4;16(1):2198. doi: 10.1038/s41467-025-57149-2. PMID: 40038251; PMCID: PMC11880362.